



Promising Data Presented at Medical Oncology Group of Australia (MOGA) 2026 Annual Scientific Meeting

SYDNEY, Australia, 12 August 2026: Filamon Limited (“Filamon”), a clinical-stage Australian drug development company bringing new concepts to the treatment of cancer, is pleased to provide a summary of data presented at the 2026 Medical Oncology Group of Australia (MOGA) Annual Scientific Meeting. The event, which attracts a range of leaders in oncology, was held from 5-7 August.

The presentation, entitled “[ADVICE Study: Phase 1 Dose Escalation in Advanced Solid Tumours – Safety and PSA Activity](#)”, presents combined clinical data from a completed Phase 0/1a trial and an ongoing Phase 1b trial testing the drug candidate, KESONOTIDE™, as an oral monotherapy in a range of late-stage solid cancers.

KESONOTIDE is a first-in-class drug that blocks the proteins, EGFR and vimentin, key drivers of tumour growth, the tumour micro-environment and cancer spread. The intended purpose of KESONOTIDE is to slow down disease progression to give standard anti-cancer therapies more time to work.

The data encompasses:

- 12 men with late-stage prostate cancer in a completed Phase 0/1 trial (PLA001 Trial)
- 9 patients with late-stage various solid cancers in an ongoing Phase 1b dose-escalation (ADVICE Trial)

To be eligible for both studies, patients needed to have confirmed disease progression based on radiographic evidence of tumour growth (RECIST). Patients were treated with KESONOTIDE only.

Confirmation of safety was a key objective across both studies given the important biological roles of EGFR and vimentin in the body and, pleasingly, KESONOTIDE has demonstrated a favourable safety profile across both trials at doses up to 60 mg daily.

Importantly, these well-tolerated doses have provided encouraging signals of the ability of KESONOTIDE to keep the disease stable (non-progressing) for periods up to 6 months in men with late-stage prostate cancer. Dose expansion and Phase 2 extension will test whether KESONOTIDE either alone or in combination with other well-tolerated anti-cancer therapies will deliver a clinically meaningful inhibition of tumour growth.

Based on this positive data, ADVICE is now poised to transition to Phase 2a by enrolling men with metastatic prostate cancer that have failed at least one line of anti-androgen (anti-hormone) therapy, and who are looking for a clinical trial or want to delay treatment with chemotherapy or radioligand therapy.

[Click here to view the presentation](#)

This announcement has been authorised by the Board of Filamon Limited.



About Filamon Limited

Filamon is an Australian, public, unlisted drug development company focused on the development of next generation drugs for age-related chronic diseases including cancer and cardiovascular, neurodegenerative and ophthalmic diseases. The Company's drug pipeline is derived from three technology platforms targeting complex signaling pathways previously considered undruggable because of their importance to healthy cell function.

The current target indications are late-stage solid cancers and chronic ophthalmic diseases including wet age-related macular degeneration (wet AMD), diabetic retinopathies and dry AMD. www.filamon.com

About KESONOTIDE

KESONOTIDE is a cyclic peptide that inhibits the ability of the inflammatory ligand, hGIIA, to activate a range of growth receptors and structural proteins important to cancer cell growth. KESONOTIDE is designed to particularly block vimentin (Type 3 intermediate filaments) and EGFR (Epithelial Growth Factor Receptor). EGFR inhibition is through lysosomal destruction via the novel process of LYTAP (Lysosome Targeting Peptides).

About MOGA 2026

The Medical Oncology Group of Australia Incorporated (MOGA) is the national, professional organisation for medical oncologists and the profession in Australia. As a specialty society of the Royal Australasian College of Physicians, MOGA maintains strong strategic alliances, working in close collaboration with professional organisations and agencies in Australia and overseas. www.moga.org.au

Contact

Media enquiries
Matthew Wright
NWR Communications
T: +61 451 896 420
E: matt@nwrcommunications.com.au

Investor/Corporate enquiries
E: corporate@filamon.com